Facebook
Twitter
LinkedIn
Forward(Day 1 Friday) MASAM SUD Pearls for Practice: The Future of Addiction Medicine 2024
CREDIT ONLY COURSE
Click on the "Program" tab to view the outline of the day
Date & Location
Date: Friday, September 13, 2024
Time: 8:00 - 5:00 pm
Location: Waltham Woods, 860 Winter Street, Waltham, MA 02451
Goal:
The goal of this educational activity aims to provide participants with the necessary knowledge, skills, and attitudes to effectively recognize and treat drug use disorders and addiction comorbidities in their professional settings. Attendees can expect to gain valuable insights from experts in the field who will share their knowledge and experiences related to drug addiction treatment, including best practices, case studies, and evidence-based approaches. The coverage on Friday will include an update from BSAS, opioid use disorder, improved patient outcomes, MOTAA, expert insights, pregnancy, and billing. On Saturday, topics will include HIV, chronic pain, Buprenorphine, harm reduction, prenatal exposure, alcohol, SUD reform, and drug testing.
Jointly Provided by:
Jointly Provided by the Massachusetts Society of Addiction Medicine & Baystate Continuing Interprofessional Education
Target Audience
This course was designed for Physicians, Physician Assistants, Pharmacists, Nurse Practitioners, OTPs, other prescribers, and social workers.
Learning Objectives
Objectives
After participating in this educational activity, attendees should be able to:
State of the state: Methadone in Massachusetts
- Assess US methadone policies in the context of policies in other countries.
- Analysis and interpretation of current Massachusetts OTP data, including outcomes, geographic access, and take home utilization.
- Discuss the future state of Massachusetts policies and regulations that will expand access to methadone.
The Final Rule: Defining Active Substance Use Disorders
- Recognize 42 CFR Part 8 Guidance for take home medications from OTPs.
- Apply a tool to assess patients for active substance use disorders, and use this to make safe, patient-centered decisions on take home medications from OTPs.
- Describe the patient experience historically of accessing Take Home Medications in the OTP setting.
Injuries and Making Substance Use Disorder Services More Accessible
- Describe the relationship between substance use disorders and brain injuries.
- Recognize the impact of brain injury on fundamental cognitive skills.
- Identify interventions and safe accommodations for supporting a person with brain injuries in Opioid Treatment Programs.
Flash Rounds: What My OTP is Doing to Improve Patient Experience & Outcomes
- Identify one patient-centered change happening at your local OTP.
- Recognize alternative approaches to missed dosing day protocols.
- Develop strategies for identifying potential risks in daily practice at your OTP
Impact of MOAA in New England: A Rural and Urban Viewpoint
- MOTAA could broaden access and retention to methadone treatment.
- Implementation of MOTAA will require pharmacy, prescriber, and medication-level considerations.
Update on Medications for Opioid Use Disorder (MOUD) in Corrections: Research and Reality
- Review of criminal justice system
- Review MOUD usage and risks in jails and recent history in MA.
- Consider practical challenges of implementing this treatment and ways to mitigate risks to the patients in carceral settings.
Expert Insights: Your Questions Answered
- Explain how the OTP model should be modernized to reduce risk and become more client centric.
- Explain how methadone can best be used safely in the age of high potency synthetic opioids.
- Explain how a clinic has met and exceeded the new regulatory changes made in April of this year.
Pregnancy
- Recognize barriers to effective contraception use in people of reproductive capacity with OUD.
- Explain one person-centered model for family planning counseling.
- Describe two possible contraception and family planning options for this population.
Friday, September 13 Methadone Day Co-sponsored by Grayken Center & BSAS | |
7:30 – 8:00 AM | Registration / Continental Breakfast / Exhibits |
7:55 – 8:00 AM | Welcome Address |
8:00 – 8:45 AM | State of the State: Methadone in Massachusetts Deirdre Calvert, MSW, LICSW |
8:45 – 9:45 AM | The Final Rule: Defining Active Substance Use Disorder Ari Kriegsman, MD; Carissa Cutler, LICSW; Kaitlyn Small |
9:45 – 10:00 AM | Break / Networking / Exhibits |
10:00 – 11:00 AM | Update on Medications for Opioid Use Disorder (MOUD) in Corrections: Research and Reality Peter D. Friedmann, MD, MPH, DFASAM, FACP; Christopher Gudas, MD, MPH |
11:00 AM – 12:00 PM | Flash Rounds: What My OTP is Doing to Improve Patient Experience & Outcomes Moderator: Ruth A. Potee, MD, DFASAM, FAAFP |
12:00 – 1:00 PM | Lunch Break |
1:00 – 1:30 PM | Impact of MOTAA in New England: A Rural and Urban Viewpoint Daniel Liauw, MD, MPH; Jeremy Morrison, DO |
1:30 – 2:30 PM | Injuries and Making Substance Use Disorder Services More Accessible Calla Harrington, LICSW, MPH; Charmaine Lastimoso, NP, MPH, CARN-AP |
2:30 – 3:30 PM | Expert Insights: You Questions Answered Mohammad Alhabbal, MD, ABFM, ABPM; Laura Kehoe, MD, MPH; Shorta Yuasa, MD, ABPM, ABEM |
3:30 – 3:45 PM | Break / Networking / Exhibits |
3:45 – 4:45 PM | Pregnancy Megan Miller, MD, FASAM; Matthew J. Rogalski, MD |
FACULTY
Name of Individual | Individual's Role in Activity | Financial Relationship Disclosure | Discussion of |
|---|---|---|---|
| Todd Kerensky, MD | Planning Committee Member | No relevant relationships with ineligible companies to disclose | No |
| James baker, MD, MPY | Planning Committee Member & Speaker | No relevant relationships with ineligible companies to disclose | No |
| Jessica Gray, MD | Planning Committee Member & Speaker | No relevant relationships with ineligible companies to disclose | No |
| Heidi Ginter, MD | Planning Committee Member | No relevant relationships with ineligible companies to disclose | No |
| Ruth A. Potee, MD | Planning Committee Member | No relevant relationships with ineligible companies to disclose | No |
| Deirdre C. Calvert, LICSW, MSW | Speaker | No relevant relationships with ineligible companies to disclose | No |
| Ari Kriegsman, MD | Speaker | No relevant relationships with ineligible companies to disclose | No |
| Kaitlyn Small | Speaker | No relevant relationships with ineligible companies to disclose | No |
| Carissa Cutler, LICSW | Speaker | No relevant relationships with ineligible companies to disclose | No |
| Christopher Gudas, MD, MPH | Speaker | No relevant relationships with ineligible companies to disclose | No |
| Jeremy Morrison, DO | Speaker | No relevant relationships with ineligible companies to disclose | No |
| Daniel Liauw, MD, MPH | Speaker | No relevant relationships with ineligible companies to disclose | No |
| Charmaine Lastimoso, MSN | Speaker | No relevant relationships with ineligible companies to disclose | No |
| Calla Harrington, MSW | Speaker | No relevant relationships with ineligible companies to disclose | No |
| Laura Kehoe, MD | Speaker | No relevant relationships with ineligible companies to disclose | No |
| Shorta Yuasa, MD | Speaker | No relevant relationships with ineligible companies to disclose | No |
| Mohammad Alhabbai, MD | Speaker | No relevant relationships with ineligible companies to disclose | No |
| Megan Miller, MD | Speaker | No relevant relationships with ineligible companies to disclose | No |
| Matthew Rogalski, MD | Speaker | No relevant relationships with ineligible companies to disclose | No |
| Peter Friedmann, MD | Speaker | No relevant relationships with ineligible companies to disclose | No |
Faculty Disclosure
The design and content of Baystate Continuing Interprofessional Education (CE) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options. Any relevant financial relationships are mitigated prior to the educational activity.
None of the other planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, Baystate Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
Baystate Continuing Interprofessional Education designates this live activity for a maximum of 7.25 (Friday) AMA PRA Category 1 Credit(s)TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity. change.
Risk Management
This activity meets the criteria for Risk Management study 7.25 hour is appropriate for risk management study.
Available Credit
- 7.25 AMA PRA Category 1 Credit™
- 7.25 BCIPE Instructional Hours
Price
Please Note: In order for your registration to be considered complete: |
|
| In order to receive CREDIT, the evaluation must be completed by: | Tue, 12/31/2024 - 3:30pm |
We appreciate your business and sincerely wish to meet your educational needs. We understand that the schedule of a busy professional, like yourself, is subject to change. Therefore, we have included information about our refund/cancellation policies for your convenience below.
Cancellation:
If you must cancel, telephone Baystate Continuing Interprofessional Education at 413-322-4242 and follow your call with a written/email request.
Specific Aids or Services:
Please call Baystate Continuing Interprofessional Education at 413-322-4242 if, under the Americans with Disabilities Act, you require specific aids or services during your visit to this continuing education program.